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Abstract
Background and aims: Early detection of Hepatocellular Carcinoma (HCC) is crucial for effective management.
Incidence of HCC has increased in the United States largely attributed to hepatitis B and C virus. Lens culinaris
agglutinin-reactive Alpha-Fetoprotein (AFP-L3) and Des-Gamma-Carboxy Prothrombin (DCP) are being recognized
specific biomarkers for HCC.
Methods: We measured AFP-L3 and DCP in serial serum specimens of a cohort of chronic hepatitis patients
on HCC surveillance and compared these markers to abdominal imaging. Among fifty patients who developed HCC
during surveillance, 30 were included in the study with available sera 1-2 years before, at diagnosis and post ablation
of HCC. For controls, three consecutive annual sera were examined from 106 chronic hepatitis patients without
HCC during surveillance for 5-10 years. The µTASWako i30 auto analyzer was used for the assay that utilizes the
microfluidics chip based assay platform. It can fractionate AFP-L3 glycoform and calculates AFP-L3% if AFP level
is ≥ 0.6 ng/mL.
Results: Combination of AFP, AFP-L3 and DCP showed high sensitivity of 83% in all patients and 75% in
patients with AFP<20 ng/mL. AFP-L3 and DCP assays were useful in patients with low levels of AFP (<20 ng/mL)
and could detect significant AFP-L3% elevation in some patients more than one year before the diagnosis of HCC.
Furthermore, AFP-L3 predicted recurrence of HCC.
Conclusions: This is the first study in the U.S. patients using the µTASWako i30 analyzer to test these HCC
biomarkers. Our results suggest that combinations of these biomarkers are highly useful for early detection of HCC.

Keywords: Hepatocellular carcinoma; Lens culinaris agglutininreactive
alpha-fetoprotein;
Des-gamma-carboxyprothrombin;
Surveillance; Risk assessment; Magnetic resonance imaging
Introduction
TIncidence of Hepatocellular Carcinoma (HCC) has been on the rise
in the United States lately attributed to an increase of chronic hepatitis
B and C [1]. Furthermore, obesity and diabetes may be additional risk
factors to an increased rate of HCC [2]. American Association for the
Study of Liver Disease (AASLD) recommends imaging studies for
surveillance for patients at risk for HCC [3]. The Ultrasound (US) is
used as the first line modality for HCC screening, followed by dynamic
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).
Imaging modalities for clinical diagnosis have changed medical practice
in HCC surveillance in recent years mitigating the risks associated with
liver biopsy. However, there are concerns for the cost and excessive
radiation exposure using imaging study for surveillance. Therefore,
the imaging techniques are usually applied annually or 6 monthly for
screening. However, doubling time of liver cancer is approximately
6 months on average [4]. To detect HCC in treatable stage, AASLD
recommends 3-6 months surveillance interval [3]. Also, National
Comprehensive Cancer Network (NCCN) Clinical Practice Guideline
on hepatobiliary cancer made similar recommendation [5]. NCCN
clinical practice guideline also recommends Alpha-Fetoprotein (AFP)
combined with imaging modalities. In general, the serum and imaging
biomarkers are specific with high positive predictive value (PPV), but
less sensitive, therefore having low Negative Predictive Value (NPV)
for HCC surveillance [6,7].
Recently two novel serum biomarkers for HCC risk assessment,
the Lectin-reactive Alpha-Fetoprotein (AFP-L3) and Des-GammaJ Med Microb Diagn
ISSN: 2161-0703 JMMD, an open access journal

Carboxy Prothrombin (DCP) have been introduced into clinical
practice. AFP-L3 is a glycosylation variant of AFP [8]. DCP is
abnormal coagulation protein produced in the liver and a precursor of
thrombin in the coagulation cascade [9]. These serum biomarkers are
highly specific for HCC [10-12]. Recently, the second generation of the
automated assays has been developed. This assay utilizes microfluidic
chip-based assay technologies. Highly sensitive serum biomarkers are
in great need for surveillance of HCC combined with high negative
predictive value. Thus, only patients with positive results would need
imaging study. Toyoda et al. showed that the high sensitivity of AFP-L3
is especially useful for patients with AFP <20 ng/mL with a lower cut-off
at 5% [13]. Hanaoka et al. demonstrated that combination of AFP-L3
and DCP further enhanced the assay sensitivity [14]. In 2007, Carr et
al. examined these markers in 98 patients with unresectable HCC in the
U.S. using Liquid Phase Binding Immunoassay (LiBASys) and reported
that the combination of AFP, AFP-L3% and DCP was superior to
individual marker alone in the diagnosis of HCC [15]. They also found
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that AFP-L3% was significantly related to portal vain invasion and
patient outcome suggesting AFP-L3% as a potential prognostic marker.
In this study, utilizing the newly developed microfluidic chip
platform (by Wako), we measured these biomarkers in the serum
samples collected prospectively from 1999 to 2011 from a cohort of
patients with chronic hepatitis without HCC, some of whom developed
HCC during the follow-up period. This patient cohort has been on
long term surveillance at the Liver Disease Prevention Center, Division
of Gastroenterology and Hepatology, Thomas Jefferson University
Hospital with 3-6 monthly AFP and biannual imaging. The majority
had chronic hepatitis B with or without cirrhosis. We investigated the
usefulness of these biomarkers for surveillance for HCC. Most subjects
have had low AFP level <20 ng/mL. This is the first study in the U.S.
using the novel and highly sensitive biomarkers assay on µTASWako
i30 analyzer for patients who are on HCC surveillance.

Patients and Methods
Patients
Included in the study were patients most of whom had Chronic
Hepatitis B (CHB) or Chronic Hepatitis C (CHC). The majority were
Asian Americans. They were on HCC surveillance with 6 monthly
AFP and 6 monthly abdominal imaging for minimum 5 years and
longer between February 1999 and August 2011. Selection of HCC
patients and controls for the study was based on the availability of
the specimens. To be eligible for the study, HCC patients had to have
sera obtained; 1-2 years before HCC diagnosis, at diagnosis and posttreatment follow up period. For controls with chronic hepatitis who
did not develop HCC during surveillance, three consecutive annual
serum samples were required. All had to have 6 monthly or annual
imaging including ultrasound. Based on the criteria, 30 HCC patients
and 106 controls were selected. HCC patients were diagnosed initially
by imaging studies including US, CT or MRI. For the final diagnosis
of HCC, the dynamic MRI was used as defined by AASLD guideline
[16-18] and by our institution [19] that shows a mass demonstrating
low to intermediate T1 signal on pre-contrast images, homogeneous,
heterogeneous, or ring enhancement during the hepatic arterial phase
and/or moderate hyperintensity on intermediate T2-weighted fat
suppressed spin-echo images with washout relative to surrounding liver
parenchyma on delayed post contrast images. To ensure that controls
did not have HCC, they were followed for 2-3 years longer after the
last serum sampling. Treatment for HCC was decided according to the
treatment guidelines for HCC in the USA [3,20-22].
The study protocol was approved by the Institutional Review
Board at Thomas Jefferson University and was in compliance with the
declaration of Helsinki.

compared to 10 ng/mL on the previous platform, LIBASys. The total
precisions for nine concentration levels of the three biomarkers were
less than 8% coefficient of variations in 21 days of evaluation. This new
assay platform has enabled the accurate measurement of AFP-L3 with
a high sensitivity and at low AFP concentrations. All processes were
preformed automatically and followed the manufacture’s instruction.

Statistical analyses
Receiver Operation Characteristic (ROC) analysis was used to
evaluate the optimum cut-off values for AFP, AFP-L3 and DCP assays
on µTASWako i30. To evaluate the diagnostic value of AFP-L3 and
DCP, sensitivity, specificity Positive Predictive Value (PPV) and
Negative Predictive Value (NPV) were estimated by using the cut-offs
which are approved by FDA and currently used in medical practice
in the USA. In addition, the optimum cut-offs were calculated. The
sensitivity, specificity, PPV and NPV for patients who have low
concentration of AFP (<20 ng/mL) were calculated. All analyses were
performed using JMP5 statistical software (SAS Institute, Cary, NC,
USA).

Results
Demographics of the study population
The study cohort consisted of 136 chronic hepatitis patients with
or without cirrhosis who have been under surveillance for HCC from
1999 to 2011.
Of the 136, 30 patients developed HCC during surveillance period
and 106 did not.
Detailed characteristics of HCC patients and controls are shown
in Table 1. In both Groups there were more men than women. HCC
patients were 10 years older in average than the controls. The majority
had chronic hepatitis B.
As shown in Table 2, of the 30 HCC patients, 26 had HBV, 3 with
HCV and one without viral infection. Details of the underlying liver
diseases including liver cirrhosis and the HBeAg status are given in the
table.
Characteristics

Patients with HCC
(n=30)

Patients without HCC
(n=106)

25 (83) / 5 (17)

69 (65) / 37 (35)

59.1 ± 10.3

48.4 ± 10.8

Gender (%)
Male/Female
Age
Mean ± SD

26 (87)/3 (10)/0 (0)/1 (3)
Infection hepatitis virus
(%) HBV/HCV/HBV+HCV/
none

105 (99)/0 (0)/0 (0)/1 (1)

AFP, AFP-L3 and DCP were measured in the serum sample
obtained 1-2 years prior to the diagnosis of HCC, at the time of
diagnosis and during the follow up period after tumor ablation (for
HCC group) and from serum samples obtained annually during which
time the absence of HCC was confirmed (for the control group).

Chronic Hepatitis/Liver
cirrhosis (%)

N/A

87 (82) / 19 (18)

≤ 2 cm

14

N/A

>2 cm and ≤ 3 cm

6

N/A

AFP, AFP-L3 and DCP were measured using a microchip capillary
electrophoresis and liquid-phase binding assay on a µTASWako i30
auto analyzer (Wako Diagnostics, Wako Life Sciences, Inc. Mountain
View, California, USA). [23]. The measurement range was 0.3-1000
ng⁄mL for AFP and 0.1-950 ng/mL for DCP. The percentage of AFP-L3
on the i30 analyzer can be calculated when AFP is over 0.6 ng⁄mL

>3 cm and ≤ 5 cm

8

N/A

>5 cm

2

N/A

Single

23

N/A

Multiple

7

N/A

Measurements of AFP, AFP-L3 and DCP

J Med Microb Diagn
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Tumor size

Number

Table 1: Patient Characteristics.
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patients with HCC
no=30

Patients without HCC
no=106

Chronic hepatitis (%)

10 (33)

87 (82)

Cirrhosis (%)

20 (66)

19 (18)

Compensated (%)

16 (53)

13(12.3)

Underlying liver disease

Decompensated (%)

4 (13)

6 (5.6)

HBsAg (+)

26 (87)

105 (99)

HBeAg (+)

5 (17)

32 (30)

HBeAg (-)

21 (70)

73 (69)

HCV

3 (10)

0 (0)

None

1 (3)

1 (1)

Table 2: Patients’ liver disease status and viral markersa.
Cut-off

Sensitivity
(%)

Specificity
(%)

PPV
(%)

NPV
(%)

AFP

200 ng/mL

13

98

67

80

AFP-L3

10%

47

98

88

87

DCP

7.5 ng/mL

13

99

80

80

Table 3: Sensitivity and Specificity of AFP, AFP-L3 and DCP in patients with and
without HCC using the current cut-off values.

Clinical performance characteristics
Table 3 shows the sensitivity (true-positive rate), specificity
(true-negative rate), Positive Predictive Value (PPV) and Negative
Predictive Value (NPV) of the AFP, AFP-L3 and DCP using current
recommended cut-offs for risk assessment in HCC surveillance from
the manufacturers. The sensitivity of AFP, AFP-L3 and DCP is 13,
47, 13% respectively based on the cut-off value for AFP, AFP-L3 and
DCP as 200 ng/mL, 10% and 7.5 ng/mL. It is noted that all three serum
biomarkers demonstrated very high but comparable clinical specificity
of greater than 98% with AFP-L3 having the highest or more than
double the sensitivity of the other two biomarkers. This suggests that
when used individually, the HCC biomarkers could be effective for
rule in diagnosis since the PPV is favorable. However it may not be as
effective for screening of patients at high risk of HCC.
Receiver Operating Characteristics (ROC) curve: The clinical
performance characteristics of the serum biomarkers are compared in
ROC analysis. Among the three HCC serum biomarkers, AFP has a
slightly greater ROC of 0.836 compared to AFP-L3 of 0.820 and DCP
of 0.728. The optimal cutoffs for AFP, AFP-L3 and DCP are 5.6 ng/mL,
4.5% and 0.57 ng/mL, respectively, and are lower than those currently
applied for clinical diagnosis.
Optimal cut-off threshold for HCC surveillance: The current
manufacturer’s recommended cut-off value may not be suited for
risk assessment in surveillance for different subgroup of chronic viral
hepatitis patients. In our study group, most patients with chronic
hepatitis and cirrhosis had HBV infection. From this data set, we
calculated the optimal cut-off thresholds for the AFP-L3 and DCP for
our study subjects.
Based on the ROC analysis of this data set, when optimal cut-offs
of 4.5% for AFP-L3 and 0.57 ng/mL for DCP were used, the sensitivity
of the AFP-L3 and DCP becomes 70% and 53.3%, respectively (Table
4). Therefore, clinical sensitivities of the AFP-L3 and DCP improve
significantly with only minor decrease in the specificity. Therefore,
these cut-offs (AFP-L3 4.5%, DCP 0.57 ng/ml) would be more useful
for risk assessment in HCC surveillance.
Combined use of the HCC serum biomarkers: The clinical
J Med Microb Diagn
ISSN: 2161-0703 JMMD, an open access journal

sensitivities of the combined AFP-L3 and DCP assays are shown in
Table 4. Notably, the sensitivity is increased to 83.3% with greater than
90% specificity for all the samples measured in the study. For patients
with AFP <20 ng/mL (n=16 HCC; and n=102 CH controls), AFP-L3
has sensitivity of 50% and DCP 48.3%. In combination, AFP-L3 and
DCP showed 75% of sensitivity and over 94% specificity. The ROC
of different combinations of the HCC serum biomarkers shows that
combination of AFP-L3 and DCP improve the AUC with 0.900
compared to AFP and AFP-L3 (0.846), AFP and DCP (0.874) and AFP,
AFP-L3 and DCP (0.874).
Changes of AFP, AFP-L3, and DCP value in patient’s overtime:
High sensitivity indicated high risk of HCC development among the
patients with chronic hepatitis and cirrhosis. Since the assays are
more sensitive to the underlying pathological changes of HCC in the
background of cirrhosis, it was important that prospectively collected
serum specimens were available long before the HCC confirmation by
MRI. Of the 30 HCC patients, 7 patients had multiple serum samples
before HCC diagnosis. As shown in (Figure 1), 6 out of 7 patients
(86%) with multiple specimens collected before the HCC diagnosis
showed elevation of AFP-L3 level (≥ 5%) of a lead time of more than 1
year before diagnosis of HCC by MRI.
Predicting HCC recurrence: Of the 30 HCC patients, 8 patients
had recurrent tumor after the initial successful ablation and had
the markers examined in the serum collected after tumor ablation.
Measurements for AFP-L3 and DCP are summarized in Table 5. Six of
the 8 patients showed elevation of either AFP-L3 level of ≥ 5% or DCP
of ≥ 0.57 ng/mL after treatment that predicted recurrence.

Discussion
Early detection of HCC at the treatable stage is imperative for
effective HCC management. Sherman suggests that HCC <3 cm in
diameter is critical for achieving successful treatment [6]. AFP, albeit
having been used for HCC diagnosis in clinical settings, is a nonspecific biomarker of HCC since it often increases in hepatic necro
inflammation [24]. It is a poor indicator of HCC with low levels of AFP
(<20 ng/mL).
In HCC surveillance, highly sensitive serum biomarkers play
important roles because of their high negative predictive values that
can minimize the false negative results of less sensitive assays. Only
patients with seropositive results may need imaging confirmation.
While the imaging modalities provide confirmative diagnosis, they are
expensive with limited access in physicians’ clinic for surveillance.
In this study, we measured serial serum specimens from a cohort
of 136 patients with chronic viral hepatitis and cirrhosis. These patients
have been closely monitored for HCC development with 3-6 monthly
Cut-off

Sensitivity
(%)

Specificity
(%)

PPV
(%)

NPV
(%)

All samples
AFP-L3

4.5%

70.0

92.5

72.4

91.6

DCP

0.57

53.3

98.1

88.9

88.1

83.3

91.3

73.5

95.1

AFP-L3 + DCP

AFP <20 ng/mL (HCC: n=16, Control: n=102)
AFP-L3

4.5%

50.0

94.1

57.1

92.3

DCP

0.57

43.8

100.0

100.0

91.9

75.0

94.1

66.7

96.0

AFP-L3 + DCP

The clinical sensitivities would be significantly improved by using the optimal cutoffs derived from this study data set and further increased by combining all three
biomarkers.
Table 4: Optimal Cut-off Values Derived from ROC Analysis for the current study.
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(ng/mL)

AFP

-30

-24

-18

-12

-6

0

(ng/mL)

(%)

AFP-L3

-30

Month before diagnosis

-24

DCP

-18
-12
-6
Month before diagnosis

0

-30

-24

-18
-12
-6
Month before diagnosis

0

The unit on x-axis is month, 0 indicates the time of HCC diagnosis; on y-axis for AFP is ng/mL; AFP-L3 is %; and DCP is ng/mL. Six of the 7 patients with multiple
serum specimens showing elevated AFP-L3 >5% one year prior to MRI confirmation, while only 2 with AFP >20 ng/mL and 1 with DCP >7.5 ng/mL (AFP-L3 superior
to others).
Figure 1: Change of AFP, AFP-L3 and DCP Value Overtime before HCC Diagnosis.
No.

Sex

Etiology

AFP

U%

1

M

2

F

3

M

4

M

5

M

DCP

HCC
/Non-HCC

Imaging

Size of
tumor (cm)

Number of
tumor

HBV

8.4

74.2

0.89

HCC

MRI

3.5x2.4

1

HBV

2419.3

9.6

0.26

HCC

MRI

1.7x1.8

1

HBV

3.1

10.7

0.24

Suspious

MRI

0.7

1

HBV

206.1

2.5

79.88

HCC

MRI

1.2

1

HBV

2.3

0.5

0.38

HCC

MRI

1.6x1.4

1

6

M

HBV

9.3

28.8

0.37

HCC

MR1

3.0, 4.0

2

7

M

HBV

3.8

0.5

0.10

HCC

MRI

2.0

1

8

M

HBV

4.3

7.0

0.11

Suspious

MRI

2.0x1.8

1

In 5 among 8 patients with specimens after successful treatment, the AFP-L3 values were elevated before the recurrence (by MRI) in comparison to only 2 each for AFP
and DCP (cut-offs for L3% 4.5 and for DCP 0.57).
Table 5: AFP, AFP-L3, and DCP in Predicting HCC Recurrence.

AFP and 6 monthly imaging for HCC for a minimum of 5-10 years.
Thirty patients who developed HCC during surveillance (26/30 with
had HBV) and 106 controls (105/106 with HBV) were enrolled. Our
study of HCC biomarkers demonstrated extremely high specificity.
Individual HCC biomarker’s sensitivity using current recommended
cut-off level is relatively low from 13% to 47%. Among these, the
sensitivity of AFP-L3 is the highest. In addition, HCC patients detected
by the individual HCC biomarkers do not overlap suggesting the
heterogeneities of HCC. The relative low sensitivity of individual
biomarkers is to be expected if used independently because each
subtype of the HCC may be defined by different biomarkers.
In the past study using the previous platform (LiBASys), DCP had
highest sensitivity and were the most accurate tumor marker, and were
suggested to be used for HCC surveillance [25]. However, AFP-L3 did
not show adequate sensitivity to be considered a surveillance tool for
HCC although it had high specificity.
In the current study, AFP-L3 on the µTASWako i30 had the
highest sensitivity using lower cut-off (5%) compared to AFP and
DCP [26]. In focusing on the patients with less than 20 ng/mL of AFP,
AFP-L3 levels were significantly higher in HCC than in non-HCC and
the sensitivity of AFP-L3 for HCC detection was more than 70% with
J Med Microb Diagn
ISSN: 2161-0703 JMMD, an open access journal

cut-off of 5%. In addition of this study, the combination of AFP-L3
and DCP improved the sensitivity reaching the level of close to 90%
and showed significantly increased AUC even in patients with low AFP
concentration.
The significant improvement of clinical sensitivity of the biomarkers
observed in this study is largely due to the novel assay technologies
that utilized microfluidics chip based assay platform. Compared to the
older version assays performed on Liquid Phase Binding Immunoassay
(LiBASys) platform, the current analyzer can fractionate AFP-L3
glycoform and calculate the percentage of AFP-L3 at the AFP level of
≥ 0.6 ng/mL, the amount which virtually cover the entire reportable
range of AFP. Sherman et al reported that a large portion of patients
(20-80%) with liver cancer would not have AFP >20 ng/mL depending
on the size of HCC at diagnosis [27]. AFP has low sensitivity for
surveillance at the current cut-off level that is designed for rule-in
HCC diagnosis. Therefore, AFP has not been recommended for HCC
surveillance by AASLD guideline [3]. Changing the cutoff threshold to
lower range would improve sensitivity but decrease specificity thereby
increasing false positivity.
In our study, we demonstrated that AFP-L3 had higher sensitivity
in all patients as well as in patients with AFP level less than 20 ng/
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mL-70% and 50%, respectively. The combination of AFP-L3 and
DCP improved the sensitivities to 83% and 75%, respectively. The
seropositive HCC biomarkers of high sensitivity could indicate the
high risk for HCC. For surveillance, a fixed cut-off is less significant
than the changes of HCC biomarkers overtime. The relatively
low sensitivity of individual serum biomarker in this study is not
unexpected since HCC is probably not a single disease entity but of
a group of liver malignancies having subtypes with different clinical
outcomes [28]. AFP, AFP-L3, and DCP may be representing different
disease subtypes. In our study, we are able to confirm the distribution
patterns of the biomarker expression as reported previously [29,30].
We also observed that not all three biomarkers are expressed in HCC
patients at the same time. AFP-L3 has been also reported as a biomarker
for aggressive HCC, while DCP is a marker of intra hepatic metastasis
[8,31]. Patients with primary malignant hepatic tumors seropositive for
AFP-L3 and low AFP concentrations present unique clinicopathologic
features. These cancers are reported having a higher incidence of nonHCC primary liver cancer derived from cholangiocytes. They also had
a high frequency of poorly differentiated tumors and sarcomatous
changes, and showed a poor prognosis [32]. Patient’s positive for
AFP-L3 and negative for DCP demonstrated histopathologic features
of more advanced HCC while those positive for DCP alone presented
infiltrative and poorly differentiated HCC [33]. Okuda et al. found that
a subgroup of Intrahepatic Cholangiocarcinoma (ICC) seropositive for
AFP-L3, and patients with combined HCC and ICC have features more
like HCC. They suggest that these liver cancers are different from the
ICC which is seropositive for CA19-9 [34]. This supports that AFP-L3
seropositive HCC is a subtype with aggressive behavior.
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